BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 16, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/13 cls
BTG plc (LSE:BGC) Jefferies Philippa Gardner Downgrade Underperform (from hold) -3% 208p
Gardner also lowered her target to 175p from 210p on absence of near-term pipeline catalysts, recent share price strength and to fully reflect R&D costs for Varisolve polidocanol endovenous microfoam to treat varicose veins. The company plans to start three Phase III trials of Varisolve by year end. Gardner also thinks the potential launch of the company's CytoFab for sepsis will be delayed by two years to 2015, with Phase IIb data anticipated in 3Q11 at the earliest. The polyclonal sheep antibody fragment against TNF alpha is partnered with AstraZeneca plc (LSE:AZN; NYSE:AZN).
Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME) Dundee David Martin Downgrade Neutral...

Read the full 826 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >